#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

Kyle LaHucik

Senior Reporter

NEW ORLEANS — Bristol Myers Squibb pulled back the curtain on its CAR-T cell therapy going after GPRC5D, and also released Phase I data for its BCMA-CD3 bispecific alnuctamab another go.

Both data drops are in patients with relapsed/refractory multiple myeloma.

Bristol Myers’s autologous CAR-T cell therapy is called BMS-986393/CC-95266, and it targets GPRC5D, which is highly expressed on multiple myeloma cells. Johnson & Johnson’s Janssen unit has a rival treatment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

Novo nabs over a third of diabetes market, a year ahead of schedule

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

#ASH22: Bris­tol My­ers re­ports next-gen CAR-T da­ta as ri­val’s bis­pe­cif­ic heads to FDA, and gives al­nuc­tam­ab an­oth­er shot

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Am­gen touts new da­ta for drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

Novo nabs over a third of diabetes market, a year ahead of schedule

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations